The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry

US-based biomanufacturer of fermentation-based ingredients, DMC Biotechnologies, has announced the availability of fermented myo-inositol for commercial use across food, beverage and supplement formulations.

Through precision fermentation and synthetic biology, DMC creates bio-based alternatives aiming to reduce carbon emissions, enhance ingredient quality and strengthen global supply chain resilience. The new ingredient launch aims to support a bio-based, solvent-free and globally scalable supply.

Myo-inositol is a naturally occurring compound found in both plants and animals. It has been used in a variety of nutrition-focused products and in recent years, it has seen growing demand due to consumers wanting more transparency, traceability and sustainability.

DMC's fermented myo-inositol is a solvent-free ingredient that supports glucose metabolism, reproductive health and infant development. According to the company, it avoids the use of processing chemicals and allows for clean label and sustainability-produced products.

“We’re proud to bring fermented myo-inositol to the market as a cleaner, more responsible alternative to traditional synthetic production methods,” said Jim Flatt, CEO of DMC Biotechnologies. “This is part of our broader strategy to deliver ingredients that support long-term supply resilience and environmental stewardship.”